- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01271075
Bilastine Updosing - Characterization of Underlying Mechanisms (BUCUM)
Double-blind, Triple Cross-over, Placebo-controlled Study to Assess the Efficacy, Mechanisms, and Safety of Treatment With Bilastine 20 mg, 40 mg and 80 mg in Cold Contact Urticaria (CCU)
This is a double-blind, triple cross-over, placebo-controlled study to assess the efficacy, mechanisms, and safety of treatment with the antihistamine bilastine in patients with cold contact urticaria (CCU).
Efficacy is primarily assessed by a change in critical stimulation time thresholds (CSTT) and critical temperature thresholds (CTT) after treatment with different dosages of bilastine (20 mg, 40 mg, 80 mg). Following a baseline period of 2-4 weeks, patients are randomized to either group A or group B. In group A they are given bilastine 20 mg, 40 mg, placebo and bilastine 80 mg for 7 days each followed by a 14-day washout period at a time. In group B they are given bilastine 80 mg, placebo, 40 mg and 20 mg for 7 days each followed by a 14-day washout period at a time. CSTT and CTT testings are performed at each of 6 visits, skin microdialysis for the assessment of mast cell mediators is performed at V2, V3 and V6. Visits for investigator's assessments are scheduled at day -14 to -28, day 0, day 7, day 28, day 49, and day 70. Overall a max. of 20 subjects with cold contact urticaria will be enrolled.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Charite-Universitatsmedizin Berlin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed consent signed and dated
- Reliable method of contraception for both women of childbearing potential as well as man during the study and 3 months thereafter. A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner
- Outpatients with CCU for more than 6 weeks. Urticaria symptoms must comprise wheal and itch.
- Age above 18 years.
- No participation in other clinical trials 1 months before and after participation in this study
Exclusion Criteria:
- Subjects who are inmates of psychiatric wards, prisons, or other state institutions. Existing or planned placement in an institution after ruling according to § 40 passage 1, number 4 AMG (Arzneimittelgesetz)
- The presence of permanent severe diseases, especially those affecting the immune system, except urticaria and cold urticaria
- The presence of permanent gastrointestinal condition which may influence the oral therapy (chronic diarrhoea diseases, congenital malformations or surgical mutilations of gastrointestinal tract)
- History or presence of epilepsy, significant neurological disorders, cerebrovascular attacks or ischemia
- History or presence of myocardial infarction or cardiac arrhythmia which requires drug therapy
- ECG alterations of repolarisation (QTc prolongations > 450ms)
- Blood pressure >180/100 mmHg and/or heart rate >100/min.
- Evidence of significant hepatic or renal disease (GOT and/or GPT 3 times above the upper reference value, serum creatinine 1.5 times above the upper reference value)
- History of adverse reactions to bilastine or known hypersensitivity to bilastine or its ingredients
- Presence of active cancer which requires chemotherapy or radiation therapy
- Presence of alcohol abuse or drug addiction
- Intake of oral corticosteroids within 14 days prior to screening visit
- Use of depot corticosteroids or chronic systemic corticosteroids within 21 days prior to screening visit
- Use of systemic immunosupressants/immunomodulators like ciclosporine A, dapsone, methotrexate, mycophenolate, chloroquine, and comparable drugs within 28 days prior to screening visit
- Pregnancy or breast-feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Bilastine A
A: Crossover Bilastine 20 mg, Bilastine 40 mg, Placebo, Bilastine 80 mg
|
Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
|
Active Comparator: Bilastine B
B: Crossover Bilastine 80 mg, Placebo, Bilastine 40 mg, Bilastine 20 mg
|
Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The effects of a standard dose (20 mg) and higher than standard doses of bilastine (40 mg and 80 mg) on symptom development in CCU patients
Time Frame: 6 visits in 12-14 weeks
|
Change in critical stimulation time thresholds (CSTT) and critical temperature thresholds (CTT) after treatment with different dosages of bilastine (20 mg, 40 mg, 80 mg).
|
6 visits in 12-14 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The effects of a standard dose (20 mg) and higher than standard doses of bilastine (80 mg) on mast cell mediator release in CCU patients
Time Frame: Visit 2 (day 0), visit 3 (day 7) and visit 6 (day 70)
|
Change in mast cell mediator release, including histamine and mast cell-derived cytokines (e.g.
IL-1, IL-6, IL-8, IL-13, TNF) after standard dose treatment with bilastine (20 mg) compared to high dose bilastine (80 mg) and baseline.
|
Visit 2 (day 0), visit 3 (day 7) and visit 6 (day 70)
|
Safety and tolerability following administration of bilastine to patients with cold contact urticaria
Time Frame: up to 14 weeks
|
Safety and tolerability: This includes physical examination, routine safety laboratory assessments, clinical observation, vital signs and adverse event reporting
|
up to 14 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Marcus Maurer, MD, Charite University, Berlin, Germany
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BUCUM 2010
- 2010-019344-39 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cold Contact Urticaria
-
Celldex TherapeuticsCompletedCold Urticaria | Symptomatic Dermographism | Cholinergic Urticaria | Cold Contact Urticaria | Symptomatic DermatographismGermany
-
Charite University, Berlin, GermanyRegeneron PharmaceuticalsCompleted
-
Charite University, Berlin, GermanyHospital del MarCompletedCold Contact UrticariaGermany
-
Charite University, Berlin, GermanyNovartis PharmaceuticalsCompleted
-
Charite University, Berlin, GermanyCompletedAcquired Cold UrticariaGermany
-
Third Harmonic Bio, Inc.TerminatedChronic Cold UrticariaNetherlands, Germany
-
Regeneron PharmaceuticalsCompletedGenetic Diseases, Inborn | Familial Cold Autoinflammatory Syndrome (FCAS) | Familial Cold Urticaria | Muckle-Wells Syndrome (MWS)United States
-
National Institute of Allergy and Infectious Diseases...Active, not recruitingHypersensitivity, Immediate | Autoinflammatory Syndromes | Physical Urticaria | Familial Cold Autoinflammatory SyndromeUnited States
-
Novartis PharmaceuticalsTerminatedChronic Spontaneous Urticaria | Cold Urticaria | Cholinergic UrticariaGermany
-
Université Catholique de LouvainRecruitingEstablishing Normative Values of Cold and Contact Heat-evoked PotentialsBelgium
Clinical Trials on Bilastine
-
Faes Farma, S.A.ORA, Inc.CompletedAllergic ConjunctivitisUnited States
-
The Affiliated Hospital of Qingdao UniversityNot yet recruiting
-
Faes Farma, S.A.CompletedChronic Urticaria | Allergic RhinoconjunctivitisAustralia, Germany, Sweden
-
Faes Farma, S.A.Charles River Clinical Services Edinburgh Ltd and CR Laboratories Preclinical... and other collaboratorsCompleted
-
A.Menarini Asia-Pacific Holdings Pte LtdUnknownPharmacokineticsChina
-
Faes Farma, S.A.Merck Sharp & Dohme LLC; Allied Research InternationalCompletedHypersensitivity | Allergic Conjunctivitis | Seasonal Allergic Rhinitis | Hay FeverUnited States
-
Menarini International Operations Luxembourg SACompletedAllergic Rhinitis | UrticariaItaly
-
Charite University, Berlin, GermanyCompleted
-
Faes Farma, S.A.Allied Research InternationalCompletedSeasonal Allergic Rhinitis | Hay Fever | RhinoconjunctivitisCanada